Evidence map›Paper›PMID 39889319›Full record

ArticleHuman immunology2025

Functional and phenotypic profiles of HLA-specific antibodies in relation to antibody-mediated kidney transplant rejection.

Margaret C Carpenter, Sweta Shrestha, Pranay Bharadwaj, Catalano Concetta, Shilpee Sharma, Joshua A Weiner, Noortje de Haan, Tamas Pongracz, Alain Le Moine, Vanda Holovska and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Margaret C CarpenterThayer School of Engineering, Dartmouth College Hanover NH USA.
Sweta ShresthaDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College Hanover NH USA.
Pranay BharadwajDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College Hanover NH USA.
Catalano ConcettaInstitute for Medical Immunology, Université libre de Bruxelles Charleroi Belgium; Department of Nephrology, Dialysis and Renal Transplantation, Hôpital Erasme, Université libre de Bruxelles Bruxelles Belgium.
Shilpee SharmaInstitute for Medical Immunology, Université libre de Bruxelles Charleroi Belgium.
Joshua A WeinerThayer School of Engineering, Dartmouth College Hanover NH USA.
Noortje de HaanCenter for Proteomics and Metabolomics Leiden University Medical Center Leiden the Netherlands.
Tamas PongraczCenter for Proteomics and Metabolomics Leiden University Medical Center Leiden the Netherlands.
Alain Le MoineDepartment of Nephrology, Dialysis and Renal Transplantation, Hôpital Erasme, Université libre de Bruxelles Bruxelles Belgium.
Vanda HolovskaHLA Laboratory, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB), Hôpital Erasme ULB Brussels Belgium.
Arnaud MarchantInstitute for Medical Immunology, Université libre de Bruxelles Charleroi Belgium.
Margaret E AckermanThayer School of Engineering, Dartmouth College Hanover NH USA; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College Hanover NH USA. Electronic address: margaret.e.ackerman@dartmouth.edu.

Funding

Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Molecular characterization and modeling efficient antibody effector functionR01AI186995 · NIAID · DARTMOUTH COLLEGE · PI Margaret E Ackerman · 2025 to 2026
$884k
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI186995NIDA NIH HHS 75N95020D00005NIGMS NIH HHS P20 GM113132ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Donor Specific Antibodies (DSAs) are associated with a higher risk of Antibody Mediated Rejection (AMR). However, not all DSAs are pathogenic, and patients that raise DSAs have a wide spectrum of outcomes ranging from the complete absence of graft injury to severe AMR. Hence, characterization of both the qualitative features and titer of DSAs has the potential to predict AMR risk and treatment outcome for sensitized patients. Here, using HLA-A2+ cell-based assays, we investigate the qualitative features of immunoglobulin G (IgG) alloantibodies including Fc receptor binding properties and Fc-mediated effector function over time. Compared to seronegative controls, reactive antibodies in seropositive participants were predominantly IgG1, and exhibited elevated levels of binding to the receptors involved in Antibody Dependent Cellular Phagocytosis (ADCP) and Antibody Dependent Cellular Cytotoxicity (ADCC) activity. Further analysis of seropositive individuals revealed that these activities were predictive ofAMR status. Collectively, these results suggest a role for phagocytic and cytotoxic antibody effector functions of DSA in contributing to graft injury.

Indexed as

Graft RejectionIsoantibodiesKidney TransplantationAdultAntibody-Dependent Cell CytotoxicityFemaleHLA AntigensHumansImmunoglobulin GMaleMiddle AgedPhagocytosisPhenotypeReceptors, FcHLA AntigensImmunoglobulin GIsoantibodiesReceptors, FcDonor specific antibodiesEffector functionKidney transplantNK cellsPhagocytosis

Identifiers

PMID39889319
PMCPMC11922655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.